Page 2 - ஓநாய் சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஓநாய் சிகிச்சை இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஓநாய் சிகிச்சை இன்க் Today - Breaking & Trending Today

Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering


Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and offering expenses payable by Werewolf, are expected to be approximately $120.0 million. Werewolf has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Werewolf. ....

New York , United States , United Kingdom , Ellen Lubman , Jalan Lada , Hc Wainwright Co , Company Contact , Scientific Communications , Exchange Commission , Equity Syndicate Prospectus Department , Syndicate Department , Evercore Group , Werewolf Therapeutics Inc , Werewolf Therapeutics , Nasdaq Global Select Market , One Federal Street , Equity Capital Markets , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஆலன் லாடா , நிறுவனம் தொடர்பு , அறிவியல் தகவல்தொடர்புகள் , பரிமாற்றம் தரகு , பங்கு கூட்டமைப்பு ப்ரோஸ்பெக்டஸ் துறை , கூட்டமைப்பு துறை ,

Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer


Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer
Veteran life sciences financial executive brings over 25 years finance and capital markets expertise
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/  Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body s immune system for the treatment of cancer, today announced the appointment of Tim Trost as Chief Financial Officer (CFO). Mr. Trost is an accomplished life sciences executive with extensive leadership experience in financial and accounting operations and strategy.
I am thrilled to welcome Tim to the Werewolf team, said Daniel J. Hicklin, Ph.D., Founder and Chief Executive Officer of Werewolf Therapeutics. Tim brings extensive experience in leading and guiding life sciences companies through different stages of developme ....

United Kingdom , Danielj Hicklin , Bayer Ag , Chimerix Inc , Coastal Physician Group Inc , Syncor International Corporation , Intecardia Inc , Argos Therapeutics Inc , Werewolf Therapeutics Inc , University Of Illinois At Urbana Champaign , Research Triangle , Asklepios Biopharmaceutical Inc , Werewolf Therapeutics , Tim Trost , Chief Financial Officer , Chief Executive Officer , Asklepios Biopharmaceutical , Senior Vice President , Vice President , Argos Therapeutics , Syncor International , Coastal Physician Group , Executive Vice President , Senior Manager , Certified Public , ஒன்றுபட்டது கிஂக்டம் ,